FDA committee recommends GSK shingles vaccine

07:46 14/09/2017
StockMarketWire.com - GlaxoSmithKline has announced that the US Food and Drug Administration's vaccines and related biological products advisory committee has voted unanimously that the data support the efficacy and safety of Shingrix for the prevention of herpes zoster (shingles) in adults aged 50 and over.

FDA advisory committees provide non-binding recommendations for consideration by the FDA, with the final decision on approval made by the FDA.

GSK senior vice-president and head of vaccines R&D, Dr. Emmanuel Hanon, said: "Shingles is a painful and potentially serious condition.

"The risk of developing shingles increases with age and it is estimated that up to one in three people in the United States will develop shingles.

"Today's vote brings us one step closer to approval of Shingrix, which is specifically designed to overcome age-related weakening of the immune system."



Story provided by StockMarketWire.com

Forex

Commodities

What the Papers Say

telegraph financial times daily mail daily express independent times
21:21 Daily briefing: NK accuses Trump; Puerto...
source: FT.com
21:18 China takes WhatsApp messaging service...
source: FT.com
21:15 Venezuela accuses Donald Trump of acting...
source: The Telegraph
21:00 Children leaving school fatter than ever...
source: The Telegraph
20:48 Dozens of British fighters on the loose in...
source: The Telegraph
20:43 5x5 bulletin for Monday 25 September:...
source: The Telegraph
20:27 UK wealth consultancy Alpha gears up for...
source: FT.com
20:17 Eminem royalties shares to be sold in IPO
source: FT.com
20:16 HBOS compensation chief criticised by Noel...
source: The Guardian
20:15 UK chip maker Imagination bought for...
source: The Guardian
[more ...]